Westover Capital Advisors LLC Purchases 6,336 Shares of Exelixis, Inc. $EXEL

Westover Capital Advisors LLC lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 15.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,719 shares of the biotechnology company’s stock after buying an additional 6,336 shares during the quarter. Westover Capital Advisors LLC’s holdings in Exelixis were worth $2,103,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Mount Lucas Management LP purchased a new stake in Exelixis in the 2nd quarter worth $599,000. Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Exelixis by 9.1% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 457,465 shares of the biotechnology company’s stock valued at $20,163,000 after acquiring an additional 38,347 shares in the last quarter. Ontario Teachers Pension Plan Board boosted its stake in shares of Exelixis by 39.5% in the second quarter. Ontario Teachers Pension Plan Board now owns 207,518 shares of the biotechnology company’s stock worth $9,146,000 after acquiring an additional 58,792 shares during the period. Intech Investment Management LLC grew its position in shares of Exelixis by 15.1% during the second quarter. Intech Investment Management LLC now owns 451,328 shares of the biotechnology company’s stock worth $19,892,000 after purchasing an additional 59,306 shares in the last quarter. Finally, Thoroughbred Financial Services LLC raised its stake in Exelixis by 80.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 18,000 shares of the biotechnology company’s stock valued at $793,000 after purchasing an additional 8,000 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Trading Up 1.8%

EXEL opened at $42.42 on Tuesday. The stock has a 50-day moving average of $39.57 and a 200 day moving average of $40.58. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62. The firm has a market cap of $11.37 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The business had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.47 earnings per share. Exelixis has set its FY 2025 guidance at EPS. On average, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Activity at Exelixis

In related news, EVP Dana Aftab sold 48,383 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the completion of the sale, the executive vice president directly owned 664,778 shares in the company, valued at $28,253,065. This trade represents a 6.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stelios Papadopoulos sold 100,000 shares of Exelixis stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. The trade was a 7.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 173,005 shares of company stock worth $7,443,678. Company insiders own 2.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Exelixis in a report on Tuesday, October 21st. Leerink Partnrs upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 21st. Stifel Nicolaus set a $43.00 price objective on shares of Exelixis in a report on Wednesday, November 5th. Royal Bank Of Canada restated a “sector perform” rating and set a $45.00 price objective on shares of Exelixis in a research report on Tuesday, October 21st. Finally, The Goldman Sachs Group started coverage on Exelixis in a research report on Wednesday, September 17th. They issued a “buy” rating and a $47.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have issued a Hold rating to the company. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average price target of $45.45.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.